Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

View Full Press Release
Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in IgA Nephropathy